ELRiSE MDS

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions (ELRiSE MDS)

More Information

Trial Status
Accepting patients
Trial Phase
Phase 3
Enrollment
300 patients (estimated)
Sponsors
Takeda Oncology
Tags
Activin Receptor IIA Inhibitor, Randomization
Trial Type
Treatment
Last Update
SparkCures ID
2232
NCT Identifier
NCT07422480

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 803-1766

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.